Moderate and severe exacerbations have a significant impact on health-related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis
Authors:
- 1 June 2020
- journal article
- review article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 78, 28-35
Abstract
Exacerbations of chronic obstructive pulmonary disease (COPD) may increase the risk of morbidity and mortality as well as pulmonary complications after surgery among patients with COPD. This meta-analysis was designed to explore the impact of moderate and severe exacerbations of COPD on health-related quality of life (HRQoL), utility, and lung function in patients with COPD. The individual impacts of moderate and severe exacerbations on St George's Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), and EuroQoL-5 dimensions 5 level (EQ-5D-5L) scores, and on forced expiratory volume in 1 s (FEV1) were assessed. Adjustments were applied to account for differences in study design. Outcomes were measured at specific time points across a 12-month study period, for all patients and for subsets with either no or ≥1 severe exacerbations in the year before study entry. The proximity of each measurement in relation to a specific exacerbation was also assessed. A total of seven randomized clinical trials (RCTs) ≥12-month interventional/observational studies with 18,746 COPD patients were assessed. Overall, 4,483 (24%) patients had ≥1 severe exacerbation in the previous year. Moderate and severe exacerbations were associated with worsening from baseline in SGRQ, CAT, EQ-5D-5L, and FEV1 measures; severe exacerbations had greater impact than moderate exacerbations. Moderate and severe exacerbations have a substantial and lasting impact on HRQoL, utility, and lung function in patients with COPD, highlighting a need for effective exacerbation prevention.Keywords
This publication has 25 references indexed in Scilit:
- Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value SetsValue in Health, 2012
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Development and first validation of the COPD Assessment TestEuropean Respiratory Journal, 2009
- Outcomes for COPD pharmacological trials: from lung function to biomarkersEuropean Respiratory Journal, 2008
- Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)European Respiratory Journal, 2008
- The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium BromideAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007
- Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up studyThorax, 2004
- Assessing the Quality of Randomized TrialsControlled Clinical Trials, 1999
- Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 1998